GlaxoSmithKline PLC
04 April 2006
Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary
Shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.
On 31 March 2006, the following Company's Non-Executive Directors were
provisionally allocated the following awards over Ordinary Shares and ADSs under
the share allocation arrangements for Non-Executive Directors for the period of
service from 1 January 2006 to 31 March 2006 as listed below.
Non Executive Director Ordinary Shares American Depository Shares
(ADS)
Sir Christopher Gent 1,660.39
Mr Lawrence Culp 519.90
Sir Crispin Davis 1,328.32
Sir Deryck Maughan 519.90
Sir Ian Prosser 913.22
Dr Ronaldo Schmitz 730.57
Dr Lucy Shapiro 129.98
Mr Tom de Swaan 249.06
Sir Robert Wilson 415.10
The Company and the directors were informed of these allocations on 3 April
2006.
This notification relates to transactions notified in accordance with Disclosure
Rule 3.1.4R(1)(b).
S M Bicknell
Company Secretary
4 April 2006
This information is provided by RNS
The company news service from the London Stock Exchange
BLBBE
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.